U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Quinoline derivatives which are 5-hydroxytryptamine antagonists

Patent 4607039 Issued on August 19, 1986. Estimated Expiration Date: Icon_subject August 19, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Re16394

1572768

1860286

Imidazolyl alkylaminopyridone and pyridinethione compounds
Patent #: 4035374
Issued on: 07/12/1977
Inventor: Durant ,   et al.

Octahydro-2H-pyrrolo[3,4-g]quinolines
Patent #: 4235909
Issued on: 11/25/1980
Inventor: Bach ,   et al.

9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor
Patent #: 4260764
Issued on: 04/07/1981
Inventor: Johnson

Heterocyclic compounds
Patent #: 4343805
Issued on: 08/10/1982
Inventor: Crossley ,   et al.

Piperid-4-yl ureas and thio ureas used as anti-depressant agents
Patent #: 4426387
Issued on: 01/17/1984
Inventor: Archibald ,   et al.

Quinoline derivatives which are 5-hydroxytryptamine antagonists Patent #: 4435405
Issued on: 03/06/1984
Inventor: Blackburn ,   et al.

Inventors

Assignee

Application

No. 06/488607 filed on 04/25/1983

US Classes:

514/312, Chalcogen attached directly to the six-membered hetero ring by nonionic bonding546/155, Plural chalcogens attached directly to the six-membered hetero ring by nonionic bonding546/157Chalcogen attached directly at 2-position by nonionic bonding

Examiners

Primary: Daus, Donald G.
Assistant: Rivers, Diana G.

Attorney, Agent or Firm

International Classes

C07D 409/00 (20060101)
C07D 409/04 (20060101)
C07D 215/18 (20060101)
C07D 215/36 (20060101)
C07D 215/00 (20060101)
C07D 215/22 (20060101)
C07D 215/227 (20060101)
C07D 333/00 (20060101)
C07D 333/24 (20060101)

Foreign Application Priority Data

1982-05-04 GB

Abstract

Compounds of the formula: ##STR1## wherein A stands for the radical --(CH2)2 -- which may optionally be substituted by one or two (1-2C)alkyl radicals; Q stands for an oxygen or sulphur atom; R° stands for a (1-4C)alkyl, (1-4C)alkoxy or cyclopropyl radical; R1 stands for a defined (3-4C)alkyl radical, a phenyl radical which may optionally bear a defined substituent, or a defined heteroaryl radical of 5 or 6 ring atoms; and R2 and R3 stand for hydrogen or a (1-2C)alkyl radical; and pharmaceutically-acceptable acid-addition salts thereof. Processes for the manufacture of said compounds. Pharmaceutical compositions comprising one of said compounds and a pharmaceutical diluent or carrier. The compounds are 5-hydroxytryptamine antagonists.

Other References

  • Gilman, et al., J. Am. Chem. Soc., vol. 71, pp. 3667-3668 (1949)
  • Westland, et al., J. Med. Chem., vol. 16(4), pp. 319-327 (1973)
  • Zayed, et al., Pharmazie, vol. 33(9), pp. 572-575 (1978)
  • Soc. Anon. pour l'Ind. a Bale, Chemical Abstracts, vol. 26, 3624 (1932)
  • A. Wander A.-G., Chemical Abstracts, vol. 43, 7974e (1949)
  • Aryuzina, et al., Chemical Abstracts, vol. 60, 7990f (1964)
  • Pettit, et al., Chemical Abstracts, vol. 61, 8271f (1964)
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?